Post-Hoc Live

Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations.Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: posthoclive@endpointsnews.com

Post-Hoc Live is a news podcast hosted by Endpoints News, with 48 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Endpoints News hosts Post-Hoc Live, a news show with 48 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #51

  Live from DC: Will Congress put a stop to China biotech deals?

  Sep 17, 202624 min

  There isn't a lawmaker on Capitol Hill who's publicly taken a more conservative stance to biopharma's deal spree in China than Rep. John Moolenaar (R-MI), chairman of the House Select Committee on China. He's been the architect of recent legislative proposals that'd clamp down on deals there and also what data regulators can review. So how did this issue rise to his attention? And how committed is he to pressing the issue? Live from Endpoints’ ⁠ China Biotech Debate: Washington, DC ⁠ ⁠ on September 15, 2026.

  ListenShow Notes
• 

  Episode #50

  Live from DC: Is secrecy the solution?

  Sep 17, 202627 min

  What do you do when you announce a drug program, then turn around and find out that there are a dozen competitors in China working on the same idea? For many US biotechs, the answer has been to hide their work as long as possible, limiting what they share with the outside world in the hope that it will keep new competitors from emerging (and passing them by). It's a tactic that's been adopted broadly in US biotech, and has led to calls for changes to the patent system. But is it a long-term solution or a short-term fix? And what are the unintended consequences of an R&D and intellectual property system that's less transparent? Live from Endpoints’ ⁠ China Biotech Debate: Washington, DC ⁠ ⁠ on September 15, 2026.

  ListenShow Notes
• 

  Episode #49

  Live from DC: What do we really mean when we talk about biosecurity risk and China?

  Sep 17, 202615 min

  Huge genetic databases. Drug ingredient supply chains. A next pandemic. War with Taiwan. Economic competition. A huge number of topics and scenarios get lumped into the "China biosecurity" conversation — some present and real, some far-fetched and far-off. So what are we really talking about when we talk about China and bio-risk? What deserves the attention and policy action? Which ones are fear-mongering? Live from Endpoints’ ⁠ China Biotech Debate: Washington, DC ⁠ ⁠ on September 15, 2026.

  ListenShow Notes
• 

  Episode #48

  Live from DC: Can the FDA steer clinical trials back to the US?

  Sep 17, 202623 min

  If investment restrictions are the potential consequences to a drug industry that's looked overseas for new assets and early trials, then what's the incentive to come back? The FDA is working to figure it out, and a new agency pilot program is meant to reinvigorate early human research in the US. But is it enough? And is the FDA moving with the urgency that many in the industry say is required? Live from Endpoints’ China Biotech Debate: Washington, DC ⁠ on September 15, 2026.

  ListenShow Notes
• 

  Episode #47

  Live from Boston: How pharma thinks about China

  Aug 7, 202624 min

  As large pharma companies increasingly turn to China to fill their pipelines, what long-term affect will it have on their strategy and operations? Pfizer's Andrew Baum shares the large drugmaker perspective on acquisitions, R&D, and how the industry could change in the years to come.Live from Endpoints’ China Biotech Debate: Boston on August 6, 2026.

  ListenShow Notes

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.